Skip to content

The changes of progesterone and inflammatory cytokines in parturients with epidural-related maternal fever during vaginal delivery

The changes of progesterone and inflammatory cytokines in parturients with epidural-related maternal fever during vaginal delivery

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048585
Enrollment
Unknown
Registered
2021-07-11
Start date
2021-10-20
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrapartum Maternal fever

Interventions

Analgesic and fever group:epidural analgesia

Sponsors

Zhengzhou Central Hospital Affiliated to Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. From July 20, 2021 to October 20, 2021, full-term first-term pregnant women who underwent natural delivery in the above two hospitals, with cervix dilation of 0-6cm; 2. Pregnant women who agree to receive labor analgesia, sign the informed consent form, and agree to draw blood and process the placenta; 3. ASA classification I-II pregnant women; 4. For a single child, the head is placed in the basin.

Exclusion criteria

Exclusion criteria: 1. Pregnant women have fever before labor and analgesia, body temperature = or > 37.5 degrees; 2. Pregnant women with fever within 1 hour after the start of labor analgesia; 3. Use of antibiotics; 4. Preterm birth, less than 36 weeks pregnant woman; 5. Placenta previa, placental abruption, severe threatened ectopic epilepsy or epilepsy, HIV positive, fetal malformation, fetal distress, pregnant women with indications for cesarean section; 6. Severe mental and nervous system diseases; 7. Suffering from diseases such as hyperthyroidism or hypothyroidism; 8. Pregnant women with diabetes, pregnancy-induced hypertension and hypertension; 9. Patients with Eisen disease, hepatitis B, hepatitis C or other serious infectious diseases; 10. Pregnant women who have previously received any radiotherapy and chemotherapy; 11. Pregnant women with abnormal liver function, kidney function, lung function or cardiac function; 12. Transfer of uterine delivery patients; 13. Abruption of membranes > 4 hours.

Design outcomes

Primary

MeasureTime frame
body temperature;Age, weight, pain relief, gestational age;Progestogens, estrogens, glucocorticoids;inflammatory factor;

Countries

China

Contacts

Public ContactJin Xiaogao

Zhengzhou Central Hospital affiliated to Zhengzhou University

jinxiaogao@yeah.net+86 18378344400

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026